Sergey A. Savko

Sergey A. Savko

Auto-generated profile, based on publicly available information

Sergey A. Savko

Sechenov First Moscow State Medical University, Moscow, Russia

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2023 in Sechenov Medical Journal
Verified
Journal Article
Open access
PDF file
EZElena Zhukovskaya
Elena Zhukovskaya
SSS. A. Savko
S. A. Savko
YOYu. A. Obukhov
Yu. A. Obukhov
AKA. F. Karelin
A. F. Karelin
AGA. P. Goncharov
A. P. Goncharov
ASAnatoly Skalny
Anatoly Skalny
Aim. To study serum concentrations of trace and macro elements and their correlations in children and adolescents after antitumor therapy, depending on the presence or absence of caries.Materials and methods. The study included 98 patients aged 4 to 17 years who were in remission after an antitumor therapy performed for acute leukemia or lymphomas. Patients with carious tooth lesions were included in group 1 (n = 34) and without caries – in group 2 (n = 64). We used inductively coupled plasma mass spectrometry to calculate the content of essential, conditionally essential and toxic elements in blood serum. The median and interquartile range were calculated, the Mann-Whitney U-test was applied to compare groups, and the Kendall rank correlation coefficient (τ) was calculated for tandem elements.Results. In both groups, the concentrations of the studied elements were within the reference ranges. In group 1, compared with group 2, higher concentrations of potassium, arsenic, iodine and boron and lower concentrations of lithium and tungsten (p < 0.05) were noted. There were no differences in the concentration of phosphorus, calcium, magnesium, manganese, gold, silver, platinum, aluminum, beryllium, bismuth, cadmium, cobalt, chromium, copper, iron, mercury, lithium, molybdenum, nickel, rubidium, antimony, tin, vanadium, zinc, zirconium and thallium between the groups. Significant correlation coefficients in both groups were obtained for the iron/manganese tandem (τ = 0.24, p < 0.05). Different values of τ were got for nickel/ manganese, cobalt/iron, manganese/phosphorus, beryllium/lithium tandems: τ = 0.342 and τ = 0.14; τ = 0.363 and τ = 0.033; τ = –0.111 and τ = –0.326; τ = –0.365 and τ = 0.42, respectively, for groups 1 and 2.Conclusion. In patients in remission after antitumor therapy, an association of caries with an increase (within reference values) in the concentration of essential (potassium, iodine) and conditionally essential elements (arsenic, boron), a decrease in the concentration of lithium and tungsten; as well as a change in the ratio of nickel/manganese, cobalt/iron, manganese/ phosphorus and change the direction of the correlation in the beryllium/lithium tandem was revealed.

30 October 2023 in Annals of Critical Care
Verified
Journal Article
Open access
PDF file
ZMZ. M. Merzhoeva
Z. M. Merzhoeva
AYAndrey Yaroshetskiy
Andrey Yaroshetskiy
SSS. A. Savko
S. A. Savko
AKA. P. Krasnoshchekova
A. P. Krasnoshchekova
Irina MandelIrina Mandel
Irina Mandel
SASergey Avdeev
Sergey Avdeev
INTRODUCTION: Therapy of COVID-19 patients with progressive lung damage after the use of glucocorticosteroids (GCS) and interleukin-6 inhibitors (IIL-6) has not yet been developed. OBJECTIVE: Assessment of the effectiveness of cyclosporine A in patients with COVID-19 with progression of lung damage and hypoxemic acute respiratory failure, who received therapy with GCS and IIL-6. MATERIALS AND METHODS: A retrospective cohort propensity-score matched analysis (n = 98). Cyclosporine A was prescribed in the first 72–96 hours after IIL-6 administration when the patient's condition worsened. The patients of comparison group corresponded to the study group, but did not receive cyclosporine A therapy. The primary end point was in-hospital mortality. Secondary endpoints — duration of hospitalization, number of patients admitted to the intensive care unit (ICU), need for respiratory support. RESULTS: Mortality was 12 (22) % in the cyclosporine group and 27 (61) % in the comparison group, р = 0.001 (hazard ratio [HR] 2.00 (1.12–3.48), р = 0.018), ICU admission rate 14 (26) % vs 29 (66) %, р = 0.001, respectively. In the cyclosporine group on day 7 CT-4, there were 26 % of patients vs 52 % in the control group, р = 0.014, the need for respiratory support (37 % vs 63.6 %, р = 0.011); saturation 88 % (82–93) vs 80 % (70–86), р = 0.001, respectively. The need for respiratory support at day 11 after IIL-6 increased the likelihood of death (HR 7.10 (2.5–20), р = 0.001). Risk factors for death: age over 57.5 years, body mass index over 30 kg/m2, hemoglobin oxygen saturation below 85.5 % on the day of IIL-6 application. Duration of hospitalization was 18.5 (14–24) days vs 18 (12–24) days, р = 0.778. CONCLUSIONS: Cyclosporine A in addition to GCS and IIL-6 for COVID-19 therapy may reduce mortality, ICU admissions, and respiratory support requirements.

25 December 2023 in Ekologiya cheloveka (Human Ecology)
Verified
Journal Article
Open access
PDF file
ODOlga V. Delyukina
Olga V. Delyukina
SSSergey A. Savko
Sergey A. Savko
ERElena V. Rylina
Elena V. Rylina
EBEkaterina A. Bilous
Ekaterina A. Bilous
TKTatiana V. Korobeynikova
Tatiana V. Korobeynikova
КВКоробейникова Татьяна Викторовна
Коробейникова Татьяна Викторовна
In recent years, epidemiological studies have increasingly recognized the significance of heavy metals as an important pathogenetic factor in many gastrointestinal diseases, particularly those associated with in gut microbiota functions. The toxicity of heavy metals towards essential intestinal microflora goes beyond causing dysbiotic disorders; it can also exacerbate intestinal infections, alter metabolic processes, and influence the development of antibiotic resistance. Since the negative effects of heavy metals are environmental in nature, there is a need to systematize the etiological role between the effects of heavy metals on the microbiome and possible nosological conditions for a more accurate approach to treatment and further research. Given the environmental origins of the abovementioned effects, there is a need to systematize the impact of heavy metals on the microbiome and their role in disease development to improve approaches to treatment and further research. We aimed to analyze the latest scientific evidence on the associations between heavy metals exposure and the intestinal microbiome and its role in the development of gastrointestinal disorders. For this scoping review we used PubMed and eLIBRARY.ru databases. We searched for keywords: «gut microbiota», «intestinal infections» (disorders), «antibiotic resistance» «heavy metals» in both Russian and English. Based on the research reviewed in this study, we can infer that heavy metals act as exogenous toxicants contributing to the development of dysbiotic, metabolic and trophic disorders of the gastrointestinal tract. They also influence the progression of infections and the development of antibiotic resistance in bacteria. Further studies should focus on exploring the toxicity of heavy metals in relation to specific populations of intestinal flora and associations with metal and antibiotic resistance. It is important to consider the therapeutic potential of microbiome modulation in the management of gastrointestinal diseases.

20 April 2023 in PULMONOLOGIYA
Verified
Journal Article
Open access
PDF file
ZMZ. M. Merzhoeva
Z. M. Merzhoeva
AYAndrey Yaroshetskiy
Andrey Yaroshetskiy
SSS. A. Savko
S. A. Savko
AKA. P. Krasnoshchekova
A. P. Krasnoshchekova
Irina MandelIrina Mandel
Irina Mandel
SASergey Avdeev
Sergey Avdeev
The optimal interval for initiating tocilizumab therapy in patients with COVID-19 (COronaVIrus Disease 2019) has not been determined. The aim of the study was to evaluate the effectiveness of prescribing tocilizumab depending on the duration of persistent hyperthermia > 38 °С in patients with SARS-CoV-2 (Severe Acute Respiratory Syndrome-related CoronaVirus 2) associated pneumonia who received tocilizumab according to the Interim Guidelines of the Ministry of Health of the Russian Federation (version at the time of inclusion in the study). Methods. A retrospective cohort study was conducted in hospitalized patients (n = 163) with SARS-CoV-2-associated pneumonia from May 2020 to May 2021. Patients were retrospectively divided into 2 groups depending on the time of tocilizumab administration: ≤ 7 days (n = 61) or ≥ 8 days (n = 102) from the disease onset. Results. Patients who received tocilizumab in the first 7 days had the lower need for CPAP (Continuous Positive Airway Pressure) therapy on day 3 after tocilizumab therapy (HR (Hazard Ratio) – 0.129 (0.039 – 0.430); p = 0.001), a higher probability of a decrease in the volume of lung lesions on computed tomography > 25% a week after the use of tocilizumab (HR – 1.065 (1.036 – 1.093); p = 0.001), the lower probability of hemoglobin oxygen saturation below 92% on day 3 (HR – 0.807 (0.750 – 0.869); p = 0.001), and day 7 (HR – 0.825 (0.772 – 0.883); p = 0.001) after tocilizumab therapy. If CPAP therapy was required on day 3 after administration of tocilizumab, each day of delay in prescribing the drug increased the risk of an adverse outcome 18-fold (HR – 18.24 (5.328 – 62.438); p = 0.001). The duration of hospitalization was significantly lower in the early group than in the late group (10 (8.5 – 15) vs 13.5 (10 – 18) days, respectively; p = 0.02). The mortality was similar (5 (8.2%) vs 6 (5.9%) patients, respectively; p = 0.748). Conclusion. The administration of tocilizumab in the first seven days from the onset of the disease in patients with COVID-19 who developed systemic inflammation and lung damage may prevent the need for escalation of respiratory support and accelerate recovery compared with the later tocilizumab administration.

27 January 2024 in Annals of Critical Care
Verified
Journal Article
Open access
PDF file
AYAndrey Yaroshetskiy
Andrey Yaroshetskiy
SSS. A. Savko
S. A. Savko
GZG. M. Zhigulin
G. M. Zhigulin
АЯАндрей Игоревич Ярошецкий
Андрей Игоревич Ярошецкий
INTRODUCTION: TRALI (transfusion-related acute lung injury) and TACO (transfusion-associated circulatory overload) are severe post-transfusion reactions with high hospital mortality, uncertainty in pathophysiologic mechanisms and a blurred clinical presentation often lead to these conditions being underdiagnosed or missed by clinicians. OBJECTIVE: To analyze and summarize the current understanding of the pathophysiology, differential diagnosis and treatment of TRALI and TACO syndrome. To highlight the best approaches and current practices to improve treatment efficacy and awareness among specialists. MATERIALS AND METHODS: Articles in the following databases were analyzed: PubMed, eLibrary. The main inclusion criteria were: free access to the full content of the publications, compliance with the review topics concerning pathophysiology, diagnosis and treatment of TRALI- and TACO-syndrome. Exclusion criteria: abstracts, conference proceedings and editorial letters, as well as publications not indexed in specialized abstract databases. RESULTS: This article presents the main reference points, thanks to which clinicians can make a differential diagnosis among posttransfusion complications and select the optimal treatment. Since TACO is a simulated cardiogenic pulmonary edema as a result of altered cytokine profile, and TRALI-syndrome is a consequence of specific immunologic conflict between donor and recipient after hemotransfusion, these conditions should be differentiated in the inpatient setting, and specialists should use the full range of modern laboratory and instrumental methods. CONCLUSIONS: Despite a large number of studies, the pathophysiologic mechanisms of TRALI and TACO remain somewhat unclear, and current approaches to diagnosis and treatment are not effective. Therefore, the existing gaps in the diagnostics of posttransfusion reactions should be clarified in further studies, and clinicians should be extra vigilant in their choice of diagnosis.